Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition for controlling glucose fluctuation

A technology for blood sugar fluctuation and composition, which is applied in the directions of drug combination, pharmaceutical formula, medical preparation containing active ingredients, etc., and can solve the problems such as the listing of drugs with blood sugar fluctuation.

Pending Publication Date: 2021-10-12
CHANGZHOU HI TECH DISTRICT MULTIPLE DIMENSION IND TECH INST
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] At present, the methods to control blood sugar fluctuations mainly include joint, continuous, and rational use of drugs, as well as through exercise, controlling and adjusting one's emotions, the law of life, and strengthening diet control. There is no specific drug for controlling blood sugar fluctuations on the market.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for controlling glucose fluctuation
  • Pharmaceutical composition for controlling glucose fluctuation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0017] Example 1: Effects on Stress Increase in Blood Glucose Caused by High Altitude Hypoxia

[0018] 72 male SD rats were randomly divided into: plain control group, plateau control group, levocarnitine 200mg / kg, 400mg / kg, 600mg / kg groups, levocarnitine 600mg+ trimetazidine 3mg / kg, each Group of 12. Rats in the plain control group were fed in a normal plain environment, and 1 hour after the last administration in the plain environment of the other groups, the rats were placed in a low-pressure hypoxic animal experiment cabin, and the pressure was 6m·s. -1 Reduce blood pressure, rise to a simulated altitude of 6000m, administer the drug by gavage in the cabin for 2 days, and drop the simulated altitude to 5000m during the administration, deprive of water and food for the last 12 hours in the cabin, and maintain a simulated altitude of 5000m for 2 hours after the last dose, and press 1.5g / kg intraperitoneal injection of 10% urethane for anesthesia, fixed in supine position, ...

Embodiment 2

[0024] Example 2: Effects on exercise-induced hypoglycemia

[0025] Kunming mice, 40, were randomly divided into blank control group, L-carnitine 300mg / kg group, 600mg / kg group and 900mg / kg group. 10ml / kg intragastric administration, 2 times a day, continuous administration for 7 days. From day 6 to day 7, fast for 12 hours. 30 minutes after the last drug administration, the mice swam with a 3% load for 30 minutes, rested for 5 minutes, and took blood to measure blood glucose and blood lactic acid levels.

[0026] The results showed that the blood sugar of the mice decreased significantly after fasting exercise, and the L-carnitine intervention group had a significantly higher blood sugar and a significantly lower blood lactic acid content than the blank control group.

[0027] group Blood sugar (mmol / L) Blood lactic acid (mmol / L) Blank control group 3.12±0.54 2.32±0.49 L-carnitine low dose group 5.72±0.43** 2.28±0.69 L-carnitine middle dose ...

Embodiment 3

[0029] Example 3: Effects on Blood Sugar Fluctuation in High Glucose Model Rats

[0030] Thirty SD rats were randomly divided into normal group, model group and levocarnitine group, 10 in each group. Preparation of animal high-glucose model: Rats were fed with high-fat and high-sugar diet for 6 weeks, fasted for 12 hours, and STZ was injected intraperitoneally at a dose of 30 mg / kg. Modeling was successful when random blood glucose > 16.7 mmol / L and remained stable for 1 week. The levocarnitine group was given 400 mg / kg intragastric administration, and the normal group and model group were given the same volume of normal saline, once a day, for 4 consecutive weeks.

[0031] Observation indicators:

[0032] 1. Intraperitoneal glucose tolerance (IPGTT), area under the curve (AUCg)

[0033] The IPGTT experiment was carried out in accordance with the IPGTT operation method established by the American Diabetes Complications Animal Model Association (AMDCC): ①Rats were strictly f...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a pharmaceutical composition for controlling glucose fluctuation. The composition is composed of one or more of levocarnitine, a levocarnitine derivative, a pharmaceutically acceptable salt of levocarnitine or the derivative thereof, a metabolic regulation drug, insulin and analogues thereof, a sulfonylurea promotor, metformin, an alpha-glucosidase inhibitor, a thiazolidinedione derivative sensitizer, a phenanthroid derivative promotor, a glucagon-like peptide-1 (GLP-1) receptor stimulant, a dipeptidyl peptidase 4 (DPP-4) inhibitor and a pancreatic amyloid polypeptide analogue, and has the effect of controlling glucose fluctuation.

Description

technical field [0001] The invention relates to the field of medicines, in particular to a pharmaceutical composition for controlling blood sugar fluctuations and its use in preparing medicines for preventing and treating blood sugar fluctuations. Background technique [0002] As we all know, diabetes is a group of metabolic diseases characterized by chronic hyperglycemia caused by a variety of etiologies. Long-term carbohydrate, fat, and protein metabolic disorders can cause multi-system damage, resulting in eye, kidney, nerve, heart, blood vessel and other tissues. Chronic progressive disease, functional decline, and failure of organs; severe disease or stress can cause acute and severe metabolic disorders, such as diabetic ketoacidosis, hyperosmolar hyperglycemia syndrome. [0003] In the past, hypoglycemic drugs were commonly used to treat hyperglycemic diseases, but hypoglycemic drugs, especially insulin preparations and sulfonylurea and non-sulfonylurea insulin secreta...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/205A61K45/06A61K38/28A61K31/155A61K31/4375A61K31/7036A61K31/495A61P3/10
CPCA61K31/205A61K45/06A61K38/28A61K31/155A61K31/4375A61K31/7036A61K31/495A61P3/10A61K2300/00
Inventor 谢和兵吕伟红顾书华
Owner CHANGZHOU HI TECH DISTRICT MULTIPLE DIMENSION IND TECH INST
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com